Early Treatment Outcomes in Pierre-Robin-Like Phenotype

May 9, 2018 updated by: University Hospital Tuebingen

Cohort Study on Prevalence and Early Treatment Outcomes in Pierre-Robin-Like Phenotype

In a longitudinal cohort study, we want to assess the effect of the pre-epiglottic baton plate, the main treatment approach currently used in Germany for Pierre-Robin-Like phenotype, on upper airway obstruction and failure to thrive using objective criteria (mixed-obstructive apnea index assessed by polysomnography, standard deviation score for body weight) upon admission and 3 months after hospital discharge.

Study Overview

Status

Completed

Detailed Description

Pierre-Robin sequence consists of a small lower jaw, a retropositioned tongue (glossoptosis), and optionally cleft palate, leading to severe upper airway obstruction and failure to thrive; occasionally even to sudden infant death. Treatment approaches are heterogeneous, some are considerably invasive; few have been evaluated by objective tests.

In a longitudinal cohort study, we want to assess the effect of the pre-epiglottic baton plate on upper airway obstruction and failure to thrive using objective criteria (mixed-obstructive apnea index assessed by polysomnography, standard deviation score for body weight) upon admission and 3 months after hospital discharge. The pre-epiglottic baton plate is the main treatment approach currently used in Germany for this condition and practised standard care in the three participating study centers.

These data will help to compare the effect of the main treatment currently used in Germany with international data on more invasive treatments used in this rare condition.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cologne, Germany, 50924
        • Centre of Competence for Oro- and Craniofacial Malformations and Department of Neonatology, Univ. Hospital of Cologne
      • Tuebingen, Germany, 72076
        • Dept. of Neonatology and Interdisciplinary Centre for Craniofacial Malformations, University Hospital Tuebingen
      • Würzburg, Germany, 97080
        • Dept. of Orthodontics and University Children's Hospital, University Hospital of Wuerzburg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 1 year (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Infants <1 year admitted with Pierre-Robin-like phenotype to participating centres

Description

Inclusion Criteria:

  • Infants < 1 year at admission, Pierre-Robin-like phenotype

Exclusion Criteria:

  • no parental consent; need for immediate tracheotomy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in mixed-obstructive apnea index (MOAI)
Time Frame: upon admission within the first year of life (before start of treatment) and 3 months after hospital discharge
Change in mixed-obstructive apnea index (MOAI) assessed by polygraphy from pre- to post-intervention as a marker of Pierre-Robin-sequence-related breathing disorder
upon admission within the first year of life (before start of treatment) and 3 months after hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in standard deviation score for body weight
Time Frame: upon admission within the first year of life (before start of treatment) and 3 months after hospital discharge
Body weight will be obtained by electronic scales and the standard deviation score for weight calculated
upon admission within the first year of life (before start of treatment) and 3 months after hospital discharge
Duration of hospital stay
Time Frame: admission within the first year of life for initiation of study intervention
admission within the first year of life for initiation of study intervention
Treatment failure
Time Frame: 3 months after admission for initiation of study intervention
3 months after admission for initiation of study intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christian F Poets, MD, Dept. of Neonatology and Interdisciplinary Centre forCraniofacial Malformations, University Hospital Tuebingen
  • Principal Investigator: Siegmar Reinert, MD, PhD, Dept. of Craniofacial Surgery, University Hospital Tuebingen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2013

Primary Completion (Actual)

August 31, 2016

Study Completion (Actual)

December 31, 2016

Study Registration Dates

First Submitted

September 30, 2014

First Submitted That Met QC Criteria

October 10, 2014

First Posted (Estimate)

October 16, 2014

Study Record Updates

Last Update Posted (Actual)

May 11, 2018

Last Update Submitted That Met QC Criteria

May 9, 2018

Last Verified

May 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe